Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430898 · ClinicalTrials.gov registry record · Phase 2
Basiliximab in Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Cerimon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT00430898 is a Phase 2 study that has completed, run by Cerimon Pharmaceuticals. The registered enrollment target is 181 participants.
The verdict
NCT00430898, a Phase 2 study, has completed, sponsored by Cerimon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.
Interventions
- DRUG Basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430898
The ClinicalTrials.gov registry entry for NCT00430898 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerimon Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Basiliximab is the first listed.
NCT00430898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430898 about?
NCT00430898 is a clinical study titled "Basiliximab in Moderate to Severe Ulcerative Colitis". The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.
What is the current status of trial NCT00430898?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2007-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00430898?
The interventions under investigation include: Basiliximab (DRUG).
Who is sponsoring clinical trial NCT00430898?
This trial is sponsored by Cerimon Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.